Recent Finacing
Recent Raise
Syndax Pharmaceuticals develops entinostat, an oral class‑I selective HDAC inhibitor and epigenetic combination therapy in late‑stage clinical development for treatment‑resistant breast and lung cancers, including immunotherapy combinations.
Focus Areas
Recent Investors
Valuation as of 09/22/2014
Total Raised
Funding rounds
Investors
